OLD National Bancorp IN trimmed its position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 40.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,284 shares of the medical equipment provider’s stock after selling 10,434 shares during the period. OLD National Bancorp IN’s holdings in Lantheus were worth $374,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. increased its holdings in shares of Lantheus by 51.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 575 shares during the last quarter. Financial Gravity Companies Inc. acquired a new position in shares of Lantheus in the fourth quarter valued at $45,000. First Quadrant L P CA acquired a new position in shares of Lantheus in the first quarter valued at $95,000. Advisor Group Inc. increased its holdings in shares of Lantheus by 1,837.2% in the fourth quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 4,152 shares during the last quarter. Finally, Meeder Asset Management Inc. increased its holdings in shares of Lantheus by 212.8% in the first quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 3,236 shares during the last quarter. Institutional investors and hedge funds own 92.98% of the company’s stock.

LNTH stock opened at $24.92 on Thursday. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.82 and a current ratio of 4.57. Lantheus Holdings Inc has a 52 week low of $12.59 and a 52 week high of $26.40. The stock has a market capitalization of $951.48 million, a P/E ratio of 26.51, a price-to-earnings-growth ratio of 1.76 and a beta of 1.52.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.03. Lantheus had a net margin of 12.17% and a return on equity of 59.57%. The business had revenue of $86.51 million for the quarter, compared to the consensus estimate of $86.80 million. On average, analysts predict that Lantheus Holdings Inc will post 1.16 EPS for the current year.

In related news, Director Brian A. Markison sold 5,000 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $25.22, for a total value of $126,100.00. Following the transaction, the director now directly owns 72,467 shares in the company, valued at $1,827,617.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mary Anne Heino sold 9,456 shares of the company’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $24.06, for a total transaction of $227,511.36. Following the completion of the transaction, the chief executive officer now owns 621,326 shares in the company, valued at $14,949,103.56. The disclosure for this sale can be found here. Insiders sold 115,102 shares of company stock worth $2,818,648 over the last 90 days. 2.60% of the stock is currently owned by corporate insiders.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Wednesday, April 24th. BidaskClub downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. TheStreet upgraded shares of Lantheus from a “c+” rating to a “b” rating in a report on Monday, March 4th. Finally, ValuEngine upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.33.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2019/05/16/lantheus-holdings-inc-lnth-position-trimmed-by-old-national-bancorp-in.html.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Article: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.